Haemonetics Corp Share Price: HAE (Haemonetics Corp) Stock Price Today & Updates | INDmoney

Question 1

What is Haemonetics Corp share price today?

Accepted Answer

Haemonetics Corp (HAE) share price today is {{live_price}}.

Question 2

Can Indians buy Haemonetics Corp shares?

Accepted Answer

Yes, Indians can invest in the Haemonetics Corp (HAE) from India.

With INDmoney, you can buy Haemonetics Corp at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Haemonetics Corp at zero transaction cost.

Question 3

How can I buy Haemonetics Corp shares from India?

Accepted Answer

It is very easy to buy Haemonetics Corp from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Haemonetics Corp be purchased?

Accepted Answer

Yes, you can buy fractional shares of Haemonetics Corp with INDmoney app.

Question 5

What are the documents required to start investing in Haemonetics Corp stocks?

Accepted Answer

To start investing in Haemonetics Corp, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Haemonetics Corp

Accepted Answer

Today’s highest price of Haemonetics Corp (HAE) is {{1_rba_end}}.

Today’s lowest price of Haemonetics Corp (HAE) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Haemonetics Corp

Accepted Answer

Today's market capitalisation of Haemonetics Corp HAE is 4.3B

Question 8

What is the 52 Week High and Low Range of Haemonetics Corp

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Haemonetics Corp is down from its 52 Week High?

Accepted Answer

Haemonetics Corp (HAE) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Haemonetics Corp is up from its 52 Week low?

Accepted Answer

Haemonetics Corp (HAE) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Haemonetics Corp?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Haemonetics Corp

Accepted Answer

Mr. Christopher A. Simon is the current Chief Executive Officer (CEO) of Haemonetics Corp.

Period	Haemonetics Corp
3 Months	-6.51%
6 Months	-3.1%
1 Year	3.78%
3 Years	-27.7%

Market Capitalization	4.3B
Book Value	$17.61
Dividend Share	0.0
Dividend Yield	3.19%
Earnings Per Share (EPS)	2.49
PE Ratio	33.84
PEG Ratio	2.01
Wall Street Target Price	106.14

Profit Margin	10.35%
Operating Margin TTM	16.11%

Return On Assets TTM	6.29%
Return On Equity TTM	15.81%

Revenue TTM	1.2B
Revenue Per Share TTM	24.51
Quarterly Revenue Growth YOY	7.000000000000001%
Gross Profit TTM	530.8M
EBITDA	288.6M
Diluted Eps TTM	2.49
Quarterly Earnings Growth YOY	-0.25

Haemonetics Corp (HAE)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Institutional Holdings

Company Information

Discover More

FAQs

EPS Estimate Current Year	2.97
EPS Estimate Next Year	3.4
EPS Estimate Current Quarter	0.89
EPS Estimate Next Quarter	0.94

	FY18	Y/Y Change
Revenue	903.9M	↑ 2.01%
Net Income	45.6M	↓ 273.49%
Net Profit Margin	5.04%	↑ 8.0%

	FY19	Y/Y Change
Revenue	967.6M	↑ 7.04%
Net Income	55.0M	↑ 20.73%
Net Profit Margin	5.69%	↑ 0.65%

	FY20	Y/Y Change
Revenue	988.5M	↑ 2.16%
Net Income	76.5M	↑ 39.09%
Net Profit Margin	7.74%	↑ 2.05%

	FY21	Y/Y Change
Revenue	870.5M	↓ 11.94%
Net Income	79.5M	↑ 3.85%
Net Profit Margin	9.13%	↑ 1.39%

	FY22	Y/Y Change
Revenue	993.2M	↑ 14.1%
Net Income	43.4M	↓ 45.42%
Net Profit Margin	4.37%	↓ 4.76%

	FY23	Y/Y Change
Revenue	1.2B	↑ 17.67%
Net Income	115.4M	↑ 166.05%
Net Profit Margin	9.87%	↑ 5.5%

	Q2 FY22	Q/Q Change
Revenue	261.5M	↓ 1.34%
Net Income	19.9M	↑ 104.06%
Net Profit Margin	7.6%	↑ 3.92%

	Q3 FY22	Q/Q Change
Revenue	297.5M	↑ 13.78%
Net Income	33.2M	↑ 67.01%
Net Profit Margin	11.16%	↑ 3.56%

	Q4 FY22	Q/Q Change
Revenue	305.3M	↑ 2.63%
Net Income	32.9M	↓ 0.76%
Net Profit Margin	10.79%	↓ 0.37%

	FY19	Y/Y Change
Total Assets	1.3B	↑ 3.02%
Total Liabilities	606.9M	↑ 25.16%

	FY20	Y/Y Change
Total Assets	1.3B	↓ 0.6%
Total Liabilities	680.0M	↑ 12.05%

	FY21	Y/Y Change
Total Assets	1.8B	↑ 43.63%
Total Liabilities	1.1B	↑ 60.04%

	FY22	Y/Y Change
Total Assets	1.9B	↑ 2.19%
Total Liabilities	1.1B	↑ 2.03%

	Q1 FY23	Q/Q Change
Revenue	304.4M	↓ 0.29%
Net Income	29.4M	↓ 10.81%
Net Profit Margin	9.65%	↓ 1.14%

	Q2 FY23	Q/Q Change
Revenue	311.3M	↑ 2.27%
Net Income	41.0M	↑ 39.68%
Net Profit Margin	13.18%	↑ 3.53%

	Q3 FY23	Q/Q Change
Revenue	318.2M	↑ 2.2%
Net Income	24.9M	↓ 39.31%
Net Profit Margin	7.83%	↓ 5.35%

	FY18	Y/Y Change
Operating Cash Flow	220.4M	↑ 37.94%
Investing Cash Flow	-63.0M	↓ 14.01%
Financing Cash Flow	-120.6M	↑ 99.7%

	FY19	Y/Y Change
Operating Cash Flow	159.3M	↓ 27.71%
Investing Cash Flow	-116.1M	↑ 84.24%
Financing Cash Flow	-50.6M	↓ 58.03%

	FY20	Y/Y Change
Operating Cash Flow	158.2M	↓ 0.67%
Investing Cash Flow	-57.2M	↓ 50.77%
Financing Cash Flow	-131.2M	↑ 159.16%

	FY21	Y/Y Change
Operating Cash Flow	108.8M	↓ 31.23%
Investing Cash Flow	-425.4M	↑ 644.09%
Financing Cash Flow	367.5M	↓ 380.05%

	FY22	Y/Y Change
Operating Cash Flow	172.3M	↑ 58.32%
Investing Cash Flow	-86.3M	↓ 79.7%
Financing Cash Flow	-15.7M	↓ 104.29%

	FY23	Y/Y Change
Operating Cash Flow	273.1M	↑ 58.51%
Investing Cash Flow	-143.8M	↑ 66.53%
Financing Cash Flow	-100.4M	↑ 537.27%

	Q2 FY22	Q/Q Change
Operating Cash Flow	42.0M	↓ 38.29%
Investing Cash Flow	-58.2M	↑ 68.68%
Financing Cash Flow	-23.4M	↑ 166.91%

	Q3 FY22	Q/Q Change
Operating Cash Flow	87.0M	↑ 107.27%
Investing Cash Flow	-31.1M	↓ 46.63%
Financing Cash Flow	-25.7M	↑ 9.79%

	Q4 FY22	Q/Q Change
Operating Cash Flow	64.4M	↓ 25.99%
Investing Cash Flow	-36.5M	↑ 17.48%
Financing Cash Flow	-49.7M	↑ 93.41%

	Q1 FY23	Q/Q Change
Operating Cash Flow	79.6M	↑ 23.59%
Investing Cash Flow	-18.0M	↓ 50.67%
Financing Cash Flow	-1.6M	↓ 96.77%

	Q2 FY23	Q/Q Change
Operating Cash Flow	19.1M	↓ 76.03%
Investing Cash Flow	-15.3M	↓ 15.24%
Financing Cash Flow	-598.0K	↓ 62.69%

	Q3 FY23	Q/Q Change
Operating Cash Flow	118.2M	↑ 519.35%
Investing Cash Flow	-40.4M	↑ 164.7%
Financing Cash Flow	-7.8M	↑ 1199.33%

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Haemonetics Corp	-2.11%	-3.1%	3.78%	-27.7%	-17.82%
Intuitive Surgical, Inc.	9.89%	-1.03%	13.36%	22.53%	83.3%
Resmed Inc.	13.96%	-24.14%	-26.27%	-20.37%	42.94%
Becton, Dickinson And Company	-1.51%	-7.34%	-8.56%	-4.28%	-1.84%
West Pharmaceutical Services Inc	1.22%	-4.24%	41.84%	29.65%	220.87%
Alcon Ag	-0.08%	-8.56%	2.35%	12.06%	24.04%

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Haemonetics Corp	Buy	$4.3B	-17.82%	33.84	10.35%
Intuitive Surgical, Inc.	Buy	$111.0B	83.3%	73.99	22.14%
Resmed Inc.	Buy	$23.8B	42.94%	26.27	20.72%
Becton, Dickinson And Company	Buy	$69.2B	-1.84%	46.72	7.66%
West Pharmaceutical Services Inc	Buy	$26.1B	220.87%	47.61	19.12%
Alcon Ag	Buy	$36.0B	24.04%	80.47	4.85%

Organization	Haemonetics Corp
Employees	3034
CEO	Mr. Christopher A. Simon
Industry	Health Technology